References
- Moises HW, Zoega T, Gottesman II. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry2, 8 (2002).
- Stefansson H, Sigurdsson E, Steinthorsdottir V et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet.71, 877–892 (2002).
- Waddington JL, Corvin AP, Donohoe G, O’Tuathaigh CMP, Mitchell KJ, Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiat. Clin. N. Amer.30, 365–399 (2007).
- Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry60, 132–140 (2006).
- Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci.9, 437–452 (2008).
- O’Tuathaigh CMP, Babovic D, O’Meara G, Clifford JJ, Croke DT, Waddington JL. Susceptibility genes for schizophrenia: phenotypic characterisation of mutant models. Neurosci. Biobehav. Rev.31, 60–78 (2007).
- Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenia patients. Schizophr. Res.100, 270–280 (2008).
- Wang XD, Su Ya, Guo CM, Yang Y, Si TM. Chronic antipsychotic drug administration alters the expression of neuregulin1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int. J. Neuropsychopharmacol.11, 553–561 (2008).
- Sei Y, Ren-Patterson R, Li Z et al. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-O-methyltransferase gene polymorphisms. Mol. Psychiatry12, 946–957 (2007).
- O’Tuathaigh CM, Babovic D, O’Sullivan GJ et al. Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1. Neuroscience147, 18–27 (2007).
- Deakin IH, Nave KA, Law AJ, Bannerman DM, Harrison PH. Behavioural characterization of neuregulin 1 (NRG1) type 1 overexpressing mice. J. Psychopharmacol.21, A58 (2007).
- Whitty PF, Owoeye O, Waddington JL. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr. Bull. DOI: 10.1093/schbul/sbn126 (2008) (Epub ahead of print).
- Chen YJ, Johnson MA, Lieberman MD et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci.28, 6872–6883 (2008).
- Hancock ML, Canetta SE, Role LW, Talmage DA. Presynaptic type III neuregulin1-ErbB signalling targets α7 nicotinic acetylcholine receptors to axons. J. Cell Biol.181, 511–521 (2008).
- Olincy A, Harris JG, Johnson LL et al. Proof of concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry63, 630–638 (2006).
- Boucher AA, Arnold JC, Duffy L et al. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of D9-tetrahydrocannabinol. Psychopharmacology192, 325–336 (2007).
- Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychosis or affective mental health outcomes: a systematic review. Lancet370, 319–328 (2007).
- Thomson PA, Christoforou A, Morris SW et al. Association of neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population. Mol. Psychiatry12, 94–104 (2007).
- Georgieva L, Dimitrova A, Ivanov D et al. Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol. Psychiatry64, 419–427 (2008).